Assay method validation of triamcinolone acetonide (TA) to support the investigation of TA-loaded nanoparticles

Christofori Maria Ratna Rini Nastiti

doi:10.14499/indonesianjpharm0iss0pp178-184

Assay method validation of triamcinolone acetonide (TA) to support the investigation of TA-loaded nanoparticles

Christofori Maria Ratna Rini Nastiti

Abstract

The aim of this study was to develop the valid analytical method which used for the assay of triamcinolone acetonide (TA) in the investigation of TA-loaded nanoparticle formulations. High Performance Liquid Chromatography (HPLC) method was applied in this study by using an Econosil column, C18 10 'm, 250 x 4.6 mm (Alltech Associates Inc, PA, USA) as the stationary phase. The mobile phase consisted of a composition of acetonitrile (ACN) and 20mM phosphate buffer solution (pH 4.2) in the proportion of 50:50 v/v. The HPLC assay of TA was validated for selectivity, linearity, precision, recovery (accuracy), sensitivity and stability of TA during the assay. Results showed that the concentration of TA in the samples can be determined against the standard in the concentration range of calibration curve. The system precision and level of recovery were considered to be acceptable, and the method was selective and sensitive.

Key words: triamcinolone acetonide, assay, validation

Full Text:

IJPDecember2009_178-184

References

Ciulla, T. A., Chriswell, M. H., Danis, R. P., Fronheiser, M., Yuan, P., Cox, T. A., Csaky K. G., Robinson, M. R., 2003, Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol;87:1032-1037.

Dollery, C.,1999, Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone Derendorf, H., Rohdewald, P., Hochhaus, G., Mollmann, H., 1986, HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. J. Pharm Biomed Anal, 4, 2, 197-206.

Gupta, V., 1982, Stability of triamcinolone acetonide solution as determined by high performance liquid chromatography. J. Pharm Sci., 72,12,1453-1456.

Jonas, J. B., Kreissig, I., Degenring R., 2005, Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res., 24, 5, 587-611

Krause, H. J., Schwarz, A., Rohdewald. P., 1985, Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int. J. Pharm, 27, 2-3, 145-155.

Kreuter, J., 1994, Nanoparticles. In: Kreuter, J., editor. Colloidal drug delivery systems. New York: Marcel Dekker

Matysová, L, Hájková R, Sicha, J., Solich, P., 2003., Determination of methyparaben, propylparaben, triamcinolone acetonide, and its degradation product in topical cream by RP-HPLC. Anal. Bioanal Chem, 376,4, 440-443

Obata, R., Iriyama, A., Inoue, Y., Takahashi, H., Tamaki, Y., Yanagi, Y.,2007, Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro. Br. J. Ophthalmol, 91, 1, 100-4.

Rechtman, E., Allen, V. D., Danis, R. P., Pratt, L. M., Harris, A., Speicher M A.,2003, Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am. J. Ophthalmol.,136, 4, 739-741.

Sieh D. H. 1982, Triamcinolone acetonide. in: Florey K, editor. Analytical profiles of drug substances. New Jersey: Academic Press; p. 619-623.

DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp178-184